Western companies concerned about China's demand for sensitive rare earths information; Irish data regulators target transparency and transfer impact assessment failures in landmark decision; and China's largest insurer plans to raise HK$11.77 billion through convertible bond listing in Frankfurt
CEO and General Counsel of MyoMed Bio, explains how legal strategy—spanning IP, regulatory compliance, and cross-border structuring—is essential for enabling clinical development, managing geopolitical and data protection risks, and aligning biotech operations across China, the U.S., and Australia.
Chinese EV giant BYD investigated in U.S. for alleged ties to Chinese Communist Party; European companies more pessimistic about doing business in China amid economic slowdown; and the world’s first intergovernmental legal organization for mediation established in Hong Kong
Chinese exporters ship goods through third countries to conceal true origin; China’s stringent cross-border data transfer rules force European pause in funding of scientific research; and Draft revisions of arbitration law aim to increase oversight and international cooperation on arbitration cases
China eases cross-border data transfer restrictions for financial institutions; Trade war prompts plan to open up service sector; and new law firm anti-money laundering regulations to align with international standards
Transfer of data across borders presents a particular compliance challenge for companies in China. Xiangxiang Ma, a partner of Anjie Broad Law Firm, analyses a new document which brings welcome practical clarification to this area
The Cyberspace Administration clarifies its approach to the export of personal and important information out of China; UK weighs whether to include China in foreign influence disclosure rules; and Burberry wins online trademark infringement suit.
China’s draft pharmaceutical trial rules aim to balance innovation with drug availability; CAC issues first rules to regulate facial recognition technology; and UBS becomes the 5th wholly foreign-owned securities firm in China.
